Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
References (9)
- et al.
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
Lancet
(1993) - et al.
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
Circulation
(1994) - et al.
Molecular biology and biochemistry of the natriuretic peptide system I: natriuretic peptides
J Hypertens
(1992) - et al.
Assay of brain natriuretic peptide (BNP) in human plasma: evidence for a high molecular weight BNP as a major plasma component in heart failure
J Clin Endocrinol Metab
(1993)
There are more references available in the full text version of this article.
Cited by (186)
Radiation-induced cardiac damage in early left breast cancer patients: Risk factors, biological mechanisms, radiobiology, and dosimetric constraints
2012, Radiotherapy and OncologyCitation Excerpt :It could be a useful tool in the evaluation of modern RT techniques, with respect to cardiac toxicity [37]. As LVEF values decreased in patients with left ventricular dysfunction or coronary artery disease [94,95], Perik et al., in the previously mentioned study, determined LVEF through radionuclide ventriculography and natriuretic peptide plasma concentrations in RT- and chemotherapy (CHT) – treated patients with left breast cancer. After a median of 2.7 years following chemotherapy and chest wall irradiation, subnormal LVEF values were observed in about 13% of the 54 patients examined [92].
Chronic Cardiac Failure
2010, Brocklehurst's Textbook of Geriatric Medicine and Gerontology
- 1
Dr. Davidson was supported by a grant from the British Heart Foundation, London, United Kingdom.
Copyright © 1996 Published by Elsevier Inc.